Home

Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

via Business Wire

Cardio Diagnostics Holdings Inc. (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company’s intellectual property portfolio. The patent, titled “Compositions and Methods for Detecting Predisposition to Cardiovascular Disease,” (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics’ founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors.

The Japanese patent further strengthens Cardio Diagnostics’ global IP strategy and adds to its robust portfolio of issued patents in the United States, Europe, Australia, India, and China, covering core technologies that helped yield the Company’s clinical solutions.

“Receiving this patent in Japan marks a critical milestone in our mission to globalize our precision cardiovascular medicine platform,” said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics. “As cardiovascular disease continues to rise in prevalence worldwide, the ability to offer AI-powered, methylation- and genetics-based diagnostics in international markets like Japan represents a major step forward in improving early detection and prevention of heart disease.”

“We are proud to support this important innovation from the University of Iowa ecosystem,” said Marie Kerbeshian, Ph.D., Executive Director of the UIRF. “Cardio Diagnostics continues to demonstrate the global relevance of its technology, and we look forward to the impact it will have in advancing cardiovascular medicine across borders.”

The Japanese patent protects Cardio Diagnostics’ novel methods and compositions that enable the detection of cardiovascular disease risk and presence using epigenetic and genetic biomarkers interpreted through advanced machine learning algorithms. This issuance underscores the global applicability of the Company’s pioneering approach to heart disease prevention.

As part of its expanding IP footprint, Cardio Diagnostics is committed to delivering innovative, data-driven solutions that empower healthcare providers and patients with actionable insights for cardiovascular health, now on a global scale.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended in December 31, 2024, and Form 10-Q for the period ended in March 31, 2025, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Contacts